MAM
FATE icon

Monaco Asset Management’s Fate Therapeutics FATE Stock Holding History

Monaco Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$972K Sell
810,000
-20,000
-2% -$24.4K 0.18% 51
2025
Q4 		$816K Buy
830,000
+60,000
+8% +$72K 0.14% 68
2025
Q3 		$970K Buy
770,000
+95,000
+14% +$102K 0.06% 67
2025
Q2 		$756K Sell
675,000
-474,708
-41% -$552K 0.13% 75
2025
Q1 		$908K Buy
1,149,708
+822,037
+251% +$1.01M 0.19% 53
2024
Q4 		$541K Buy
327,671
+190,000
+138% +$479K 0.08% 71
2024
Q3 		$482K Sell
137,671
-149,229
-52% -$581K 0.07% 65
2024
Q2 		$941K Sell
286,900
-29,905
-9% -$131K 0.15% 47
2024
Q1 		$2.33M Sell
316,805
-1,866,423
-85% -$11.6M 0.7% 28
2023
Q4 		$8.17M Buy
2,183,228
+335,284
+18% +$791K 2.4% 12
2023
Q3 		$3.92M Buy
1,847,944
+842,718
+84% +$2.79M 1.16% 22
2023
Q2 		$4.78M Buy
1,005,226
+34,933
+4% +$193K 1.34% 21
2023
Q1 		$5.53M Buy
970,293
+720,293
+288% +$4.35M 1.7% 17
2022
Q4 		$2.52M Buy
+250,000
New +$4.7M 0.76% 37

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monaco Asset Management's FATE Position: Q1 2026 in Review

Monaco Asset Management reduced its Fate Therapeutics (FATE) stake by 2.4% in Q1 2026, selling an estimated $24.4K and leaving 810,000 shares worth $972K. The position accounts for 0.18% of the portfolio, ranked #51.

Monaco Asset Management first reported a position in FATE in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.17M in Q4 2023. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Monaco Asset Management held 810,000 shares of Fate Therapeutics worth $972K as of Q1 2026.
  • Monaco Asset Management sold 20,000 Fate Therapeutics shares in Q1 2026, an estimated $24.4K.
  • Fate Therapeutics made up 0.18% of Monaco Asset Management's portfolio in Q1 2026, its #51 holding.
  • Monaco Asset Management first reported a position in Fate Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Monaco Asset Management's Fate Therapeutics position peaked at $8.17M in Q4 2023.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Monaco Asset Management's 13F filing for Q1 2026, filed 11 May 2026.